Your blood test came back with something flagged next to CRP. Maybe it reads 4.2 mg/L. Maybe it just says "elevated inflammatory markers" and leaves you to work out the rest.
That phrase does a lot of work in a consultation room and almost none on a printout. Inflammation is not a diagnosis. It is a signal that something has raised a protein your liver makes — an infection, an injury, excess visceral fat, an autoimmune process, or a cold you barely noticed. Here is what elevated inflammatory markers mean, how to read hs-CRP against the bands cardiologists use, and where the evidence is strong versus genuinely contested.
What "inflammatory markers" refers to
There is no single inflammation test. The phrase covers proteins and cell counts that move when your innate immune system is active:
- C-reactive protein (CRP) — made by the liver, driven largely by interleukin-6. It rises within hours and falls within days, which makes it the most responsive of the group.
- ESR — an indirect, slower measure reflecting fibrinogen. It lags CRP in both directions.
- Ferritin — an iron storage protein that is also an acute-phase reactant, which is why inflammation makes iron stores look better than they are.
- Fibrinogen — a clotting protein that also rises with inflammation.
- White blood cell count — non-specific, but a persistently high count alongside high CRP points to an active process.
Homocysteine is often listed with these, but it is a different animal: a methylation intermediate, not an acute-phase protein. It carries cardiovascular risk information, but it will not move because you have a chest infection. For the full panel, see our breakdown of inflammation markers and what each adds.
CRP is the one worth understanding properly: cheap, fast, responsive, and the only one with a formal cardiovascular risk framework attached.
Standard CRP versus hs-CRP
Both measure the same protein; they differ in how low they resolve. A standard CRP assay is built for acute illness and generally cannot distinguish values below roughly 3-5 mg/L — it reports "normal" and stops. A high-sensitivity assay resolves to about 0.1-0.3 mg/L.
The cardiovascular risk signal sits entirely in that low range. For prevention, order hs-CRP; for suspected infection, standard CRP is the right test.
The hs-CRP risk bands
The categories most labs use come from a 2003 joint scientific statement by the American Heart Association and the CDC:
| hs-CRP (mg/L) | AHA/CDC category | Practical reading |
|---|---|---|
| Under 1.0 | Low relative cardiovascular risk | Typical of lean, active, non-smoking adults |
| 1.0 to 3.0 | Average relative risk | The band most adults fall into |
| Above 3.0 | High relative risk | Roughly double the risk of the lowest band |
| Above 10.0 | Not a cardiovascular reading | Active inflammatory or infectious process; repeat when well |
Two caveats. These are relative risk bands — a 25-year-old and a 65-year-old at 3.5 mg/L do not carry the same absolute risk. And the 2018 AHA/ACC cholesterol guideline uses a different number: hs-CRP at or above 2.0 mg/L is a "risk-enhancing factor" that can tip an intermediate-risk adult toward a statin. Both are real; they answer different questions. Our guide to optimal versus normal ranges covers why that gap exists.
One reading is not a result
CRP has high within-person variability. A 2024 systematic review and meta-analysis in PLOS ONE found a median within-subject coefficient of variation of about 44% for hs-CRP across 11 studies, with estimates from 27% to 76%. Concretely: a true value of 2.0 mg/L can produce single readings anywhere from roughly 1.0 to 3.5 mg/L on different days, with nothing about your health having changed.
The AHA/CDC statement anticipated this and recommended two measurements at least two weeks apart, using the lower as your stable baseline. Fasting is not required.
So a single hs-CRP of 3.4 mg/L is not a finding. Two readings of 3.4 and 3.1 mg/L a month apart, taken while you were well, is.
What raises CRP that has nothing to do with your arteries
| Cause | Typical effect on CRP |
|---|---|
| Acute bacterial infection | Large — often 50 to several hundred mg/L |
| Viral infection, recent vaccination | Moderate, transient over days |
| Surgery, injury, hard exercise | Transient rise over 24-72 hours |
| Obesity | Sustained low-grade rise; adipose tissue secretes IL-6 |
| Smoking | Sustained; reverses over months after quitting |
| Oral estrogen (combined pill, oral HRT) | Sustained rise via first-pass liver effect |
| Autoimmune disease (RA, lupus, IBD) | Variable, tracks disease activity |
| Periodontal disease, sleep apnea | Modest but sustained |
| Chronic kidney disease | Sustained |
| Statin therapy | Lowers hs-CRP, partly independent of its LDL effect |
The oral estrogen row is the one most often missed: it raises CRP through hepatic first-pass metabolism without a matching rise in vascular inflammation. Transdermal estrogen largely does not.
Where the evidence is strong, and where it is not
Prediction: strong. A 2023 collaborative analysis in The Lancet by Ridker and colleagues pooled 31,245 statin-treated patients from the PROMINENT, REDUCE-IT and STRENGTH trials. Highest versus lowest quartile, hs-CRP predicted major adverse cardiovascular events at an adjusted hazard ratio of 1.31 (95% CI 1.20-1.43), cardiovascular death at 2.68 (2.22-3.23) and all-cause death at 2.42 (2.12-2.77). The matching LDL-C figures were 1.07 (0.98-1.17), 1.27 (1.07-1.50) and 1.16 (1.03-1.32). In people already on a statin, residual inflammation predicted outcomes more strongly than residual cholesterol.
Causation: contested, and probably not. A mendelian randomisation analysis by the CRP CHD Genetics Collaboration (BMJ, 2011) covered 194,418 participants including 46,557 coronary heart disease cases. Observed CRP associated with CHD at a risk ratio of 1.33 (1.23-1.43) per standard deviation; genetically raised CRP, which lifestyle cannot confound, gave 1.00 (0.90-1.13). Their conclusion: CRP itself is unlikely to be even a modest causal factor.
Lowering it on purpose: mixed. This is the live question:
- JUPITER (2008) randomised 17,802 adults with LDL under 130 mg/dL and hs-CRP at or above 2.0 mg/L to rosuvastatin and cut events sharply (HR 0.56, 0.46-0.69) — but statins lower LDL too, so it cannot isolate inflammation.
- CANTOS (2017) tested canakinumab, an IL-1-beta antibody, in 10,061 post-heart-attack patients. The 150 mg dose reduced events (HR 0.85, 0.74-0.98) with no change in LDL — the first clean signal that lowering inflammation alone can help. The effect was modest and fatal infections rose.
- CIRT (2019) tested low-dose methotrexate and found no benefit. It also failed to lower IL-6 or CRP.
- Colchicine succeeded in COLCOT (2019) and LoDoCo2 (2020); a low-dose formulation won FDA approval in 2023 for cardiovascular risk reduction.
- ZEUS (2026) tested ziltivekimab, an IL-6 inhibitor, in over 6,300 patients with atherosclerotic disease, chronic kidney disease and hs-CRP at or above 2 mg/L. It lowered IL-6 and hs-CRP as expected and did not reduce cardiovascular events (HR 0.99, 0.88-1.11).
Taken together: hs-CRP is a powerful risk marker and, so far, a disappointing drug target. Read it as a thermometer, not a thermostat — treat a persistently elevated result as serious information, and address what is causing it rather than the number itself.
What to do about a confirmed elevated hs-CRP
Assuming two readings two weeks apart, both taken while well, both above 3 mg/L:
- Reduce visceral fat. The largest modifiable driver in most people — adipose tissue is an endocrine organ that secretes IL-6.
- Exercise consistently. Aerobic and resistance training both lower CRP over months. A single hard session raises it briefly, so do not test the next day.
- Fix sleep. Short and fragmented sleep raise inflammatory markers within days; untreated sleep apnea is a common hidden cause.
- Stop smoking. Large effect, reverses over months.
- Eat a Mediterranean-style pattern. Our protocol for lowering CRP ranks interventions by effect size, and the omega-3 index test shows whether your fish intake is landing.
- See a dentist. Periodontal disease is underrated here.
Retest after 8 to 12 weeks. Inflammation moves faster than most biomarkers, but not in days.
When this needs a doctor, not a protocol
- A repeat hs-CRP above 10 mg/L when you feel well
- Inflammation with unexplained weight loss, fever, night sweats, or persistent joint swelling
- A steady upward trend across three or more tests despite lifestyle change
- Elevated CRP with anemia, a high white cell count, or abnormal liver or kidney markers
These warrant a workup for autoimmune disease and occult infection. hs-CRP is not a cancer screen.
Where CRP fits in a wider panel
Inflammation is one axis of cardiovascular risk, not the whole picture. It reads best alongside ApoB, Lp(a), fasting insulin and blood pressure — which is how the longevity blood panel is built. hs-CRP is also one of nine inputs to the PhenoAge algorithm, so you can see its weighting in our biological age calculator. Vitamin D status interacts with inflammatory signalling, which is one reason vitamin D deficiency and high CRP often appear together.
How Merios helps
Merios reads hs-CRP off your uploaded results and tracks it over time — the only way to separate a real trend from the noise a single reading cannot escape. It flags the pattern rather than the point, against your lipids and glucose.
Track your inflammation with Merios
This article is for informational purposes only and does not constitute medical advice. Discuss abnormal inflammatory markers and cardiovascular risk assessment with your physician.